OIS@AAO

PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

By Tom Salemi | November 14, 2013

PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving…

Read More

Ophthotech Introduces Their Antigen for WetAMD

By Tom Salemi | November 14, 2013

David Guyer, CEO, discusses their novel anti-PDGF antigen for Wet AMD. Using FlowVista in combination with standard of care anti-VEGF therapy, David expands on the…

Read More

iCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema

By Tom Salemi | November 14, 2013

iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which…

Read More

Eleven Biotherapeutics Gets to the Root of Ophthalmic Diseases

By Tom Salemi | November 14, 2013

Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s…

Read More

Physician Entrepreneurship in Ophthalmology

By Tom Salemi | November 14, 2013

Striving to reach the aspiring entrepreneurs in the crowd at the 5th Annual Ophthalmology Innovation Summit @ AAO in New Orleans, Dick Lindstrom leads an…

Read More

Ophthalmic Innovation 2013 – “A View from the AAO”

By Tom Salemi | November 14, 2013

David Parke, CEO for the American Academy of Ophthalmology, speaks to the audience of the 5th Annual Ophthalmology Innovation Summit @ AAO, about the importance,…

Read More

Alternative Financing Strategies

By Tom Salemi | November 14, 2013

Charles Warden, Managing Director for Versant Ventures, initiates this finance focused panel by detailing the funding gap that has been referred to often at the…

Read More

Developing an Effective Dialogue with the FDA

By Tom Salemi | November 14, 2013

Moderating an informative conversation surrounding FDA procedures and communication, Emmett Cunningham, Summit Chairman, draws detailed responses from Wiley Chambers and Malvina Eydelman of the FDA.…

Read More

The Ophthalmology Market – “A View from the Public Sector”

By Tom Salemi | November 14, 2013

Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for JPMorgan, gladly addresses the audience at the 5th Annual Ophthalmology Innovation Summit…

Read More

2013 Ophthalmology Innovation Summit Innovator Awards

By Tom Salemi | November 14, 2013

William J. Link PhD, Managing Director for Versant Ventures, announces the winners of the 2013 OIS Innovator Award. Describing the caliber and achievement that merits…

Read More

Going Public – Who, When, and Why?

By Tom Salemi | November 14, 2013

Detailing the grueling process and levels of determination necessary to go public, David Guyer, CEO for Ophthotech, begins this panel discussion with some of the…

Read More

The NEI Continues to Explore the Root Cause of Glaucoma

By Tom Salemi | November 14, 2013

Ophthalmic Innovation 2013 – “A View from the NEI” Paul Sieving, Director for the National Eye Institute, leads the attendees at the 5th Annual Ophthalmology…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.